Oct. 20 at 1:26 PM
$IFRX Whats a Win?
Current standard-of-care efficacy CSU, ~50-60% of patients respond partially to omalizumab (Xolair)
$RHHBY but complete control is rare (<40%). Also why Roche often mentioned as a buyout.
In HS, adalimumab
$ABBV achieves HiSCR (primary endpoint) in ~50% at week 12, but placebo rates are ~25-30%, leaving high unmet need. Also why Abbie often mentioned as buyout candidate.
In CSU, Historical Phase 2 benchmarks: Barzolvolimab
$CLDX hit rapid UAS7 reductions in >50% with good tolerability; EVO756 showed 30% complete response at week 4. No yet approved.
A "win" for
$IFRX would mean clinically meaningful improvements over baseline, with rapid onset (e.g., by week 4) to highlight the oral, non-immunosuppressive profile.
Even 25-35% responders with dose-dependent signals would signal upside, as it proves C5a inhibition works in antihistamine-refractory patients.
**Differentiated MOA is significantly needed with no 1 drug doing the trick**
Remember
$MLTX ?
